Literature DB >> 9201256

Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections.

S Haraguchi1, R A Good, G J Cianciolo, R W Engelman, N K Day.   

Abstract

Studies of the effects of retroviruses on the immune system, which date back through thirty years of investigations, are reviewed. In the earliest published studies in the 1960s, it was demonstrated that mice infected with oncogenic viruses were immunosuppressed. Since then, numerous articles have been published describing profound immunodeficiencies observed in vivo in humans infected with human immunodeficiency virus and in animals such as cats infected with the feline immunodeficiency virus. In vitro investigations have shown that inactivated retroviruses or transmembrane envelope protein p15E as well as a synthetic 17-amino acid peptide (CKS-17) impressively conserved within the transmembrane envelope protein of several animal or human retroviruses are highly immunosuppressive. More recently, dysfunction of cytokines produced by CKS-17 at both a cellular and molecular level have been found to mimic influences observed in vivo in patients infected with the human immunodeficiency virus. CKS-17 has also been shown to induce cAMP in vitro. The significance of these observations to understanding the immunological disturbances observed in malignancy, cytokine biosynthesis, and modulations of immune functions through cAMP is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201256     DOI: 10.1002/jlb.61.6.654

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  18 in total

1.  Retroviruses push the envelope for mammalian placentation.

Authors:  Harmit Singh Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-26       Impact factor: 11.205

2.  HIV-1 envelope gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes.

Authors:  H Ueda; O M Howard; M C Grimm; S B Su; W Gong; G Evans; F W Ruscetti; J J Oppenheim; J M Wang
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

3.  Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents.

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Int J Clin Rheumtol       Date:  2011-08

4.  Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production.

Authors:  Z Zídek; D Franková; A Holý
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo.

Authors:  Wendy Fitzgerald; Andrew W Sylwester; Jean-Charles Grivel; Jeffrey D Lifson; Leonid B Margolis
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  Tumor cells expressing a retroviral envelope escape immune rejection in vivo.

Authors:  M Mangeney; T Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

7.  A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Authors:  Géraldine Schlecht-Louf; Marianne Mangeney; Hanane El-Garch; Valérie Lacombe; Hervé Poulet; Thierry Heidmann
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

Review 8.  A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways.

Authors:  Soichi Haraguchi; Robert A Good; Noorbibi K Day-Good
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Immune abnormalities induced by human endogenous retroviral peptides: with reference to the pathogenesis of systemic lupus erythematosus.

Authors:  Toshio Naito; Hitoshi Ogasawara; Hiroshi Kaneko; Takashi Hishikawa; Iwao Sekigawa; Hiroshi Hashimoto; Naoki Maruyama
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

10.  Multitasking: Making the Most out of the Retroviral Envelope.

Authors:  Mariana Varela; Massimo Palmarini
Journal:  Viruses       Date:  2010-08-02       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.